Phase 1 Trial of ABBV-706, an Antibody-Drug Conjugate Targeting SEZ6, in Patients with Advanced Small Cell Lung Cancer and Other Solid Tumors

By
Lauren Averett Byers
Byoung Chul Cho
Alissa J. Cooper
Anne C. Chiang
Ji-Youn Han
Muhammad Furqan
Afshin Dowlati
Daniel Morgensztern
Kyriakos P. Papadopoulos
Noura J. Choudhury
María Vieito
Jair Bar
Joo-Hang Kim
Wallace Akerley
Tae Min Kim
Young-Chul Kim
Luis Paz-Ares
Myung-Ju Ahn
Hiroshi Yokouchi
Darius Meiman
Wijith Munasinghe
Oluwadamilola Ogunyankin
Nadine Jahchan
Song Wang
Cristiano Ferlini
Randy R. Robinson
Frederick J. Kohlhapp
Tammy Palenski
Guillermo Rivell
Pooja Hingorani
Sreenivasa Chandana
June 1, 2026

Nature Medicine

Objective:

The primary aim of this trial was to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ABBV-706 in patients suffering from relapsed or refractory solid tumors, with a particular focus on those diagnosed with relapsed or refractory small cell lung cancer (SCLC) and other advanced solid tumors.

Approach:

Study Design: This study was a first-in-human, open-label, phase 1 trial that involved adult patients with advanced solid tumors. Participants received ABBV-706 intravenously every three weeks.
Cohorts: The trial included several cohorts, such as dose-escalation and optimization cohorts specifically for patients with SCLC, a safety lead-in cohort, and expansion cohorts. The study evaluated specific dose levels of 1.8 mg/kg and 2.5 mg/kg.
Endpoints: The primary endpoints of the study were centered on safety and tolerability. Secondary endpoints were designed to evaluate pharmacokinetics, immunogenicity, and antitumor activity.

Key Findings:

ABBV-706 monotherapy exhibited a manageable safety profile, indicating that it can be administered without significant adverse effects.
The overall response rate (ORR) observed in the trial was 43.8%. Notably, the ORR was higher at 60.9% among patients with relapsed or refractory SCLC, suggesting a potential enhancement in efficacy compared to existing treatment options.

Interpretation:

The preliminary results from this trial indicate that ABBV-706 may have promising antitumor activity in patients with relapsed or refractory SCLC, highlighting the need for further investigation to validate these findings.

Limitations:

It is important to note that the study is still ongoing, and the results presented are preliminary.
The sample size for certain cohorts may restrict the generalizability of the findings, and potential biases inherent in the study design should be taken into account.

Conclusion:

ABBV-706 appears to be a promising treatment option for patients with relapsed or refractory SCLC, and further studies are warranted to confirm these initial findings and explore its potential in broader patient populations. ---

Phase 1 Trial of ABBV-706, an Antibody-Drug Conjugate Targeting SEZ6, in Patients with Advanced Small Cell Lung Cancer and Other Solid Tumors

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Related Content

Toward Precision Cardio-Oncology in Breast Radiotherapy

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma